Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 9 of 9 results for topotecan

  1. Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

    Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

    Technology appraisal guidance
    Published
    25 November 2009
    View recommendations

    Sections for TA184

  2. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

    Technology appraisal guidance
    Published
    28 October 2009
    View recommendations

    Sections for TA183

  3. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

    Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

    Technology appraisal guidance
    Published
    27 April 2016
    View recommendations

    Sections for TA389

  4. Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]

    In development [GID-TA11423] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Past appeals and decisions

    - paclitaxel (review) 12 November 2002 TA389 Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel,...

  6. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

    NICE guideline
    Last updated
    8 March 2024

    Sections for NG122

  7. Ovarian cancer - topotecan (TA28)

    This guidance has been replaced by NICE technology appraisal guidance 91.

    Technology appraisal guidance
    Published
    23 July 2001

  8. Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (TA45)

    This guidance has been updated and replaced by NICE technology appraisal guidance 91.

    Technology appraisal guidance
    Published
    19 July 2002

  9. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (TA91)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Technology appraisal guidance
    Published
    25 May 2005